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OBJECTIVE — Hyperglycemia is a risk factor for microvascular complications and may in-
crease the risk of cardiovascular disease in patients with type 2 diabetes. This study tested the
LDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentfor
improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy.
RESEARCH DESIGN AND METHODS — A 26-week, randomized, double-blind,
placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004and
August 2006 to evaluate the efﬁcacy and safety of colesevelam for reducing A1C in adults with
type 2 diabetes whose glycemic control was inadequate (A1C 7.5–9.5%) with existing sulfonyl-
urea monotherapy or sulfonylurea in combination with additional oral antidiabetes agents. In
total, 461 patients were randomized (230 given colesevelam 3.75 g/day and 231 given placebo).
The primary efﬁcacy measurement was mean placebo-corrected change in A1C from baseline to
week 26 in the intent-to-treat population (last observation carried forward).
RESULTS — The least squares (LS) mean change in A1C from baseline to week 26 was
0.32% in the colesevelam group and 0.23% in the placebo group, resulting in a treatment
differenceof0.54%(P0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaseline
toweek26was16.1%inthecolesevelamgroupand0.6%intheplacebogroup,resultingin
a treatment difference of 16.7% (P  0.001). Furthermore, signiﬁcant reductions in fasting
plasma glucose, fructosamine, total cholesterol, non–HDL cholesterol, and apolipoprotein B
were demonstrated in the colesevelam relative to placebo group at week 26.
CONCLUSIONS — Colesevelam improved glycemic control and reduced LDL cholesterol
levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.
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H
yperglycemia is a risk factor for mi-
crovascular complications in pa-
tients with type 2 diabetes (1), and
landmark clinical studies have docu-
mented that improved glycemic control
results in decreased development and
progression of the microvascular compli-
cations of type 2 diabetes (2–5). The
American Diabetes Association (ADA)
recommendsanA1Ctargetof7.0%(6),
thelevelatwhichclinicaltrialshavedem-
onstrated fewer long-term microvascular
complications(7).Althoughtheimpactof
hyperglycemia on macrovascular compli-
cationsisunknown,individualswithtype
2 diabetes have a two- to fourfold higher
risk for initial coronary events, and more
importantly, those developing coronary
heart disease have a relatively poor prog-
nosis for recurrent coronary heart disease
events and coronary death (8,9). In addi-
tion to hyperglycemia, dyslipidemia and
hypertensionalsocontributetotheriskof
complications in patients with type 2 di-
abetes. Therefore, treatment regimens for
type 2 diabetes should aim to address
multiple clinical features of this disease.
Effective lipid management reduces
macrovascular disease and mortality in
individuals with type 2 diabetes, particu-
larly in those who have had prior cardio-
vascular events (10–12). However, in a
study by Kennedy et al. (13), the ADA
goal of LDL cholesterol 100 mg/dl (2.6
mmol/l) was achieved by only 49% of pa-
tients with type 2 diabetes, and only 16%
achievedLDLcholesterol70mg/dl(1.8
mmol/l), the optional goal for very-high-
risk individuals. Individuals with type 2
diabetes may exhibit a characteristic dys-
lipidemia that includes elevated triglycer-
ide levels, decreased HDL cholesterol
levels, and small dense LDL particles,
whichincreasestheriskofcomplications.
Preliminaryevidencesuggeststhatal-
tering bile acid metabolism with a bile
acid sequestrant in patients with type 2
diabetes has a beneﬁcial effect on glucose
control. Colesevelam HCl (Welchol
[colesevelam]; Daiichi Sankyo), a speciﬁ-
callyengineeredbileacidsequestrantthat
signiﬁcantlylowersLDLcholesterollevels
in patients with primary hypercholester-
olemia, improved glycemic control in
adults with type 2 diabetes based on post
hoc analysis of data from a 6-month pri-
mary lipid trial. A short-term, double-
blind, placebo-controlled pilot study in
subjects with type 2 diabetes inade-
quatelycontrolledwithmetforminand/or
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12 weeks, colesevelam reduced A1C by
0.50% in the total population (P  0.007
vs. placebo) and by 1.0% in those with a
baseline A1C 8.0% (P  0.002 vs. pla-
cebo) (14). A subsequent study in which
colesevelam was added to insulin-based
therapy showed that the addition of
colesevelam reduced A1C by 0.5% rela-
tive to placebo after 16 weeks (15). The
present study was designed to evaluate
the longer-term efﬁcacy of colesevelam
for improving glycemic control and the
lipid proﬁle in patients with type 2 diabe-
tes not adequately controlled on a stable
sulfonylurea-based antidiabetes regimen.
RESEARCH DESIGN AND
METHODS— This 26-week, ran-
domized, double-blind, placebo-
controlled, parallel-group study was
conducted at 49 sites in the U.S. and 2 in
Mexico. The study protocol was con-
ducted in compliance with institutional
review board regulations, good clinical
practice guidelines, and the 4th amend-
ment of the Declaration of Helsinki. All
individuals provided written informed
consent.
This study enrolled adults with type 2
diabetes that was inadequately controlled
(A1C 7.5–9.5%, inclusive) on a stable dose
of sulfonylurea alone or in combination
with additional oral antidiabetes agents for
90 days. All subjects were advised to fol-
low ADA dietary recommendations.
Subjects were excluded for the fol-
lowing reasons: LDL cholesterol 60
mg/dl (1.6 mmol/l); triglycerides 500
mg/dl (5.7 mmol/l); BMI 45 kg/m
2;u n -
controlled hypertension (blood pressure
160/95 mmHg); history of type 1 diabe-
tes, ketoacidosis, dysphagia, swallowing
disorders, or intestinal motility disorders;
any serious medical/psychiatric disorder;
drug/alcohol abuse within 2 years; hospi-
talization within 14 days; treatment with
colesevelam within 8 weeks; chronic use
or recent initiation of insulin; participa-
tion in a weight loss program with ongo-
ing weight loss; starting an intensive
exercise program within 4 weeks; use of
anyinvestigationaldrugwithin30daysof
the ﬁrst dose of study medication; or any
condition or therapy that may pose a risk
or make participation not in the best in-
terest of the subject.
Subjects taking oral corticosteroids,
cholestyramine, and colestipol were ex-
cluded. Subjects on oral contraceptives,
hormone replacement therapy, thyroid
replacement therapy, and lipid-altering
drugs(HMG-CoAreductaseinhibitors,ﬁ-
brates, niacin, ﬁsh oils, and cholesterol
absorption inhibitors) were included
provided a stable dose had been main-
tained for 30 days before the initiation
of the study and dosage changes were not
anticipated.
Subjects were discontinued for hy-
perglycemia if A1C increased to 10.0%
orfastingplasmaglucose(FPG)increased
to 260 mg/dl (14.4 mmol/l) and was
conﬁrmed within 3 days. The manage-
ment, reporting, and actions taken in re-
sponse to hypoglycemia (FPG 60 mg/
dl) were left to the judgement of the
investigators. Discontinuation was con-
sideredonlyafterrepeatedmeasurements
of hypoglycemia.
Subjects underwent a 1-week screen-
ingperiodandthenentereda2-weeksin-
gle-blind placebo run-in period, during
which subjects took six placebo tablets
per day. Subjects chose their preferred
dosing regimen: three tablets with the
noon and evening meals or six tablets
with the evening meal. The dosing regi-
men selected was to be maintained
throughout the double-blind treatment
period for an individual subject. Follow-
ing the placebo run-in period, subjects
were randomized 1:1 to colesevelam 3.75
g/day (six tablets: 625 mg/tablet) or
matchingplacebofor26weeksofdouble-
blind treatment. Subjects continued
taking their prestudy oral antidiabetes
medication(s)atthesamedoseandtime
as before the start of the study.
The primary efﬁcacy parameter was
mean change in A1C from baseline to
week 26 in the intent-to-treat (ITT) pop-
ulation with the last observation carried
forward (LOCF) analysis. Secondary efﬁ-
cacyparametersincludedmeanchangein
FPG, fructosamine, and C-peptide; mean
changeinA1Cforthesulfonylureamono-
therapy and sulfonylurea combination
therapy cohorts; percentage of subjects
achieving a reduction in FPG 30 mg/dl
or A1C 0.7%; mean change and mean
percent change in lipids, lipoproteins,
and lipid and lipoprotein ratios; and me-
dian change and median percent change
in high-sensitivity C-reactive protein
(hsCRP)andtriglycerides.Forallsecond-
ary efﬁcacy parameters, the change from
baseline to week 26 was calculated using
both LOCF and non-LOCF analyses.
All blood samples were obtained un-
der fasting conditions. Tests were per-
formed by a certiﬁed laboratory (Medical
Research Laboratories International,
Highland Heights, KY). Total cholesterol
and triglycerides were measured by en-
zyme assay. HDL cholesterol was mea-
sured by cholesterol oxidase assay of the
supernatant from the precipitate of non-
HDL lipoproteins with heparin and man-
ganese chloride. Apolipoprotein (apo)B,
apoA-I, and hsCRP were quantitated by
immunonephelometry. The method used
to calculate LDL cholesterol was based on
triglyceride concentration at screening
(Friedewald equation for subjects with
triglycerides 400 mg/dl [4.5 mmol/l]
and Lipid Research Clinic -quantiﬁca-
tion method for subjects with triglycer-
ides 400 mg/dl [4.5 mmol/l] and 500
mg/dl [5.7 mmol/l]). The method of LDL
cholesterol determination used at screen-
ing was used throughout the study for an
individual subject, regardless of changes
in triglycerides.
Safety assessments included treat-
ment-emergent adverse events (AEs),
clinical laboratory tests, changes in vital
signs, and physical examinations. Com-
pliance with the medication regimen was
evaluated by counting unused tablets.
Statistical method
TheITTpopulationwastheprimaryanal-
ysis population for all efﬁcacy parameters
and included all randomized subjects
whotookatleastonedoseoftherandom-
ized study medication and had a baseline
and at least one postbaseline A1C mea-
surement.Analysesofthemeanchangein
A1C from baseline were conducted for
two mutually exclusive protocol-deﬁned
cohorts: subjects on background sulfo-
nylurea monotherapy and those on back-
ground sulfonylurea combination
therapy. The safety population included
all randomized subjects who took at least
one dose of study medication.
This study required 400 randomized
subjectsandhad86–95%powertodetect
adifferenceofa0.50–0.80%reductionin
mean A1C from baseline between
colesevelam and placebo (with a two-
sided type I error at 0.05), assuming a
common SD of 1.5% and a maximum
dropout rate of 15%.
Comparisons between the treatment
groups in age, weight, height, BMI, A1C,
and FPG at baseline were evaluated using
a one-way ANOVA model with treatment
as a factor. Sex and race were tested using
a Fisher’s exact/Fisher-Freeman-Halton
test. An ANCOVA model with treatment
and concomitant antidiabetes medication
status as ﬁxed effects and baseline A1C as
a covariate was used to evaluate the treat-
ment effect. The normality assumption of
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conducting the ANCOVA. When a signif-
icant departure from normality was ob-
served, a nonparametric equivalent of
ANCOVA (rank ANCOVA) was applied.
The treatment effect in A1C change
from baseline with LOCF was estimated
andpresentedasleast-squares(LS)mean,
SEM, corresponding two-tailed 95% CI,
andtwo-sidedPvalue.Secondaryefﬁcacy
parameters were compared with the same
statistical methodology unless otherwise
noted.
Median change and median percent
change in hsCRP and triglycerides were an-
alyzed using a nonparametric ANCOVA
model. The treatment difference was esti-
mated by the Hodges-Lehmann estimator,
and a two-tailed 95% CI for the treatment
difference was obtained using the method
of Moses. The glycemic-control response
rate was tabulated and compared using
Pearson’s 
2 test.
RESULTS
Subject disposition and baseline
characteristics
The study was conducted between Au-
gust 2004 and August 2006. A total of
1,180 subjects were screened, and 493
entered the placebo run-in period. In to-
tal,461subjectswererandomized(230to
the colesevelam and 231 to the placebo
groups), with 307 subjects completing
the 26-week study (Fig. 1). Baseline de-
mographic characteristics did not differ
between the colesevelam and placebo
groups at randomization (Table 1).
Sixty-foursubjectsinthecolesevelam
groupwithdrewbeforestudycompletion,
relative to 90 subjects in the placebo
group. Twenty-two subjects in the
colesevelam group discontinued due to
glycemia-related events, relative to 46
subjects in the placebo group. Sixteen
subjects in the colesevelam group and 39
in the placebo group discontinued due to
protocol-speciﬁed discontinuation crite-
ria(FPG260mg/dl[14.4mmol/l],A1C
10.0%, or change in antidiabetes regi-
men). Mean compliance was similar dur-
ing the double-blind treatment period
(92.7% of the colesevelam group and
90.8% of the placebo group).
Efﬁcacy: glycemic parameters
Colesevelam reduced A1C by 0.32 
0.066%, whereas placebo increased A1C
by 0.23  0.065%, resulting in a signiﬁ-
cant LS mean treatment difference of
0.54  0.090% at week 26 by LOCF
(P  0.001; Fig. 2A and online appendix
Table 1 [available at http://dx.doi.org/
10.2337]). Similar treatment effects were
observed in the sulfonylurea mono-
therapy (0.79  0.154%, P  0.001)
and sulfonylurea combination therapy
(0.42  0.110%, P  0.001) cohorts.
A1C was also evaluated by stratifying
the total population into two subgroups
according to baseline A1C to evaluate the
effect of baseline A1C on the response to
the addition of colesevelam. In the sub-
group with A1C 8.0% at baseline, the
treatment effect for A1C was 0.48 
0.124% (P  0.0002). A greater A1C
treatment effect was observed in the sub-
group with A1C 8.0% at baseline
(0.58  0.128%, P  0.0001).
A signiﬁcant LS mean treatment dif-
ference in FPG was observed by week 26
by LOCF (13.5  5.14 mg/dl [0.75 
0.29 mmol/l], P  0.009; online appen-
dix Table 1), with a signiﬁcant treatment
difference observed as early as 6 weeks
(13.7  3.98 mg/dl [0.76  0.22
mmol/l], P  0.001).
A signiﬁcantly greater percentage of
subjects in the colesevelam group
achieved an A1C reduction 0.7% com-
pared with those in the placebo group
(35.2 vs. 16.5%, respectively, P  0.001;
online appendix Table 2). In addition,
there was a signiﬁcantly greater number
of individuals in the colesevelam group
relative to the placebo group who
achieved either a reduction in A1C
0.7% or a reduction in FPG 30 mg/dl
by study end (104 [47.5%] vs. 70
[32.1%], respectively, P  0.001; online
appendix Table 2). A signiﬁcant LS mean
treatment difference in fructosamine was
reported at week 26 by LOCF (21.4 
4.59 	mol/l, P  0.001). There was no
signiﬁcant LS mean treatment difference
in C-peptide at week 26 by LOCF
(0.17  0.101 ng/ml, P  0.102).
Lipid parameters
Signiﬁcant LS mean percent treatment
differences in LDL cholesterol, non–HDL
cholesterol, triglycerides, total choles-
terol, apoA-I, and apoB were observed af-
ter 26 weeks of treatment with
colesevelam relative to placebo (P 
0.001 for all; Fig. 2B). The LS mean per-
centchangeinLDLcholesterolfrombase-
Figure 1—Subject disposition.
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the colesevelam group and 0.6% in the
placebo group, resulting in a treatment
difference of 16.7% (P  0.001). In ad-
dition, a signiﬁcant mean percent reduc-
tion in non-HDL cholesterol, total
cholesterol, and apoB concentrations oc-
curred in the colesevelam group relative
to the placebo group at week 26 (LOCF),
while a signiﬁcant mean percent increase
in apoA-I concentration occurred with
colesevelam relative to placebo. Although
mean HDL cholesterol increased from
baseline by week 26 in both the
colesevelam and placebo groups (0.5 vs.
0.3%, respectively), there was no signiﬁ-
cant treatment difference by week 26
(LOCF; 0.1%, P  0.916). Median tri-
glyceride levels increased with colesevelam
relative to placebo treatment (19.5 vs.
1.0%), resulting in a signiﬁcant LS mean
percent treatment difference at week 26
(LOCF; 17.7%, P  0.001).
Signiﬁcant LS mean treatment differ-
ences between the colesevelam and pla-
cebo groups were reported in the ratios of
total cholesterol to HDL cholesterol
(0.24  0.08), LDL cholesterol to HDL
cholesterol (0.43  0.05), non–HDL
cholesterol to HDL cholesterol (0.24 
0.08), and apoB to apoA-I (0.08 
0.01) at week 26 (LOCF; P  0.003 for
all).
Inﬂammatory markers
There was an LS median treatment differ-
ence of marginal signiﬁcance in hsCRP by
week26(LOCF;0.404.50mg/l,P
0.063).
Safety
Colesevelamwasgenerallysafeandwell
tolerated in subjects with type 2 diabe-
tes when added to sulfonylurea-based
therapy. In total, 145 subjects in the
colesevelam group and 126 in the pla-
cebo group experienced an AE during
this study (online appendix Table 3).
The most frequently reported AEs with
colesevelam were constipation, upper
respiratory tract infection, and urinary
tract infection, and upper respiratory
tract infection, headache, and naso-
pharyngitis were more common with
placebo. Forty-seven subjects in the
colesevelam group and 21 in the pla-
cebo group experienced a drug-related
AE, with constipation being the most
common drug-related AE in both
groups (6.1 vs. 2.6%, respectively).
Most AEs were mild to moderate in se-
verity, although nine subjects in the
colesevelam group and seven in the pla-
cebo group experienced a severe AE.
Three severe AEs were judged to be
drug-related (two in the colesevelam
group and one in the placebo group).
Eighteen subjects in the colesevelam
group and nine in the placebo group
withdrew due to an AE, mostly gastro-
intestinal in nature. Twelve subjects in
the colesevelam and four in the placebo
group withdrew due to a drug-related
AE. There were 8 serious AEs in the
colesevelam group and 11 in the pla-
cebo group; however, none was drug-
related.
Six subjects in the colesevelam group
experienced hypoglycemia relative to two
subjects in the placebo group. None of
these hypoglycemic episodes was consid-
ered severe, and no subject in either
groupdiscontinuedduetohypoglycemia.
Meanchangesinsafetylaboratoryparam-
eters and vital signs were similar between
the groups during the randomized treat-
mentperiod.Noweightgainwasnotedin
either group; mean weight change was
0.01 kg in the colesevelam group and
0.4 kg in the placebo group.
Table 1—Demographic characteristics (randomized population)
Colesevelam
HCl Placebo P
n 230 231
Age (years) 56.6  10.3 57.0  10.3 0.670
Sex 0.575
Male 128 (55.7) 122 (52.8)
Female 102 (44.3) 109 (47.2)
Race/ethnicity 0.438
Caucasian 135 (58.7) 128 (55.4)
Hispanic 66 (28.7) 59 (25.5)
African-American 23 (10.0) 34 (14.7)
Asian 4 (1.7) 7 (3.0)
Other 2 (0.9) 3 (1.3)
Weight (kg) 95.0  22.6 92.5  20.2 0.197
BMI (kg/m
2) 33.1  5.95 32.5  5.64 0.225
A1C (%) 8.2  0.68 8.3  0.72 0.054
FPG (mg/dl) 176.6  46.5 181.0  50.4 0.323
Concomitant antidiabetes medication status
Sulfonylurea monotherapy 75 (32.6) 81 (35.1)
Glibenclamide 39 (52.0) 44 (54.3)
Glipizide 24 (32.0) 25 (30.9)
Glimepiride 10 (13.3) 12 (14.8)
Tolbutamide 1 (1.3) 0
Gliclazide 1 (1.3) 0
Sulfonylurea combination therapy 154 (67.0) 150 (64.9)
Concomitant antidiabetes medications in the
sulfonylurea combination therapy group*
Sulfonamides, urea derivatives 120 (77.9) 122 (81.3)
Glipizide 62 (40.3) 50 (33.3)
Glibenclamide 37 (24.0) 50 (33.3)
Glimepiride 21 (13.6) 21 (14.0)
Tolazamide 1 (0.6) 2 (1.3)
Biguanides 104 (67.5) 105 (70.0)
Thiazolidinediones 40 (26.0) 40 (26.7)
Biguanide/sulfonamide ﬁxed-dose
combinations
33 (21.4) 27 (18.0)

-glucosidase inhibitors 0 1 (0.7)
Other antidiabetes agents† 13 (8.4) 10 (6.7)
Data are means  SD and n (%) unless otherwise indicated. *Some subjects took more than one oral
antidiabetes agent in combination with background sulfonylurea therapy, and thus the total number of
concomitant oral antidiabetes agents in the columns exceed then values in the colesevelam HCl and placebo
columns. †Other antidiabetes agents includes ﬁxed-dose rosiglitazone/metformin, ﬁxed-dose glipizide/met-
formin, nateglinide, and repaglinide.
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tigated the glucose-lowering effect of
colesevelaminpatientswithtype2diabe-
tes when added to an existing regimen of
sulfonylurea, alone or in combination
with additional oral antidiabetes agents.
Colesevelam resulted in a signiﬁcant
meanA1Creduction(0.54%)byweek26
in the total population, with the sulfonyl-
ureamonotherapyandsulfonylureacom-
bination therapy cohorts reporting a
signiﬁcant reduction at week 26 as well
(0.79and0.42%,respectively).Whilethe
magnitude of A1C reduction may appear
modest, it is similar to the observed effect
from another study in which a new an-
tidiabetes agent was combined with a sul-
fonylurea in patients with advanced type
2 diabetes (16). Importantly, individuals
with declining -cell function would be
expected to be heavily represented in this
population (17).
The lower dropout rate with
colesevelam (27.8%) compared with
placebo (39.0%) was likely related to
treatment failure, as many patients dis-
continued in the placebo group due to
meeting protocol-speciﬁed discontinu-
ation criteria, attesting to the efﬁcacy of
colesevelam. Furthermore, colesevelam
produced signiﬁcant reductions in LDL
cholesterol, total cholesterol, non-HDL
cholesterol, and apoB by week 26, sup-
porting its use as a novel treatment for
improving glycemic control with added
lipid beneﬁts for patients with type 2
diabetes.
There was a rise in triglyceride levels
in patients receiving colesevelam in this
study (17.7%, P  0.001 vs. placebo).
This is a known and expected phenome-
nonwithbileacidsequestrants.Although
hypertriglyceridemia is a cardiovascular
disease risk factor, the effect of elevated
triglyceride levels in patients on existing
statin therapy, or in the context of a re-
duction in LDL cholesterol, remains to be
determined. Current studies are address-
ing the contribution of triglyceride levels
to cardiovascular outcomes (18,19). Im-
portantly, the rise in triglyceride with
colesevelam was accompanied by a re-
duction in LDL cholesterol (16.7%) and
apoB (6.7%) and an increase in apoA-I
concentration (3.8%, P  0.001 vs. pla-
cebo for LDL cholesterol, apoB, and
apoA-I). Hence, the overall effect of
colesevelam on circulating lipid levels
may be interpreted as reassuring.
The exact mechanism(s) through
whichcolesevelamdemonstratesitseffect
on glycemic control is unknown. Poten-
tial explanations include the following: 1)
bile acid sequestrants act in the gastroin-
testinal tract, reducing the amount of glu-
cose absorbed and/or altering the time
course of glucose absorption (20); and/or
2) bile acid sequestrants bind bile acids,
thus disrupting the enterohepatic path-
way of bile metabolism, which has indi-
recteffectsonglucosemetabolism(21).It
is known that bile acids are endogenous
ligands of the farnesoid X receptor (FXR),
a member of the nuclear receptor super-
family of ligand-activated transcription
factors (22) that play an important role in
bile acid, cholesterol, and glucose metab-
olism. There is a complex interplay be-
tween FXR and additional nuclear
receptors, including the liver X receptor,
hepatocyte nuclear factor-4
 receptor,
andtheﬁbroblastgrowthfactor-19recep-
tor. Little is currently known about how
bile acids affect these pathways, particu-
larly in patients with type 2 diabetes
whose glucose regulation is impaired.
Further research is needed to determine
the mechanism underlying the glucose-
lowering effect of colesevelam.
It is increasingly recognized that con-
trolling hyperglycemia and cholesterol
levels may afford better outcomes in pa-
tientswithtype2diabetes(23).Inspiteof
this,approximatelytwo-thirdsofindivid-
uals with type 2 diabetes fail to achieve
the ADA-recommended goal of A1C
7.0%, and almost 75% do not achieve
the LDL cholesterol goal of 100 mg/dl.
Thus, new treatment regimens that can
improve both glycemic control and lipid
management in individuals with type 2
diabetes would be clinically beneﬁcial.
This study showed that colesevelam sig-
niﬁcantly reduced A1C and LDL choles-
terolconcentrationinpatientswithtype2
diabetes when added to a sulfonylurea-
Figure 2—A: Mean change in A1C (%) from baseline to weeks 6, 12, 18, and 26 (LOCF) in the
ITTpopulation.*P0.001vs.placebo.B:Meanpercentchangeinlipidandapoparametersfrom
baseline to week 26 (LOCF) in the ITT population. *P  0.001 vs. placebo. †Triglycerides (TGs)
reported as median rather than mean.
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safe and well tolerated in this study. No
patientreportedasevereepisodeofhypo-
glycemia, and none discontinued due to
hypoglycemia. Furthermore, colesevelam
did not result in weight gain.
The positive effects of colesevelam in
patients with type 2 diabetes reported in
this study suggest that the bile acid se-
questrant colesevelam may represent a
novel therapeutic add-on strategy for im-
proving multiple metabolic parameters in
patients with type 2 diabetes.
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